---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-035337"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:14:09.412394+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics receives sixth U.S. patent for GTx-104 dosing regimen; protection extended to 2043

## Summary
- US Patent 12,414,943 issued for I.V. nimodipine dosing regimen used in Phase 3 STRIVE-ON trial.
- First method-of-use patent for GTx-104; adds to five composition patents expiring 2037.
- Patent protection for GTx-104 extended to 2043.
- GTx-104 is a clinical-stage injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
- Orphan Drug Designation provides 7 years of marketing exclusivity upon FDA approval.

## SEC filing metadata
- accession: 0001140361-25-035337
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125035337/0001140361-25-035337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125035337/ef20055717_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-035337
- JSON: https://secwatch.observer/filing/0001140361-25-035337.json
- Plain text: https://secwatch.observer/filing/0001140361-25-035337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.